INM-089 IVT formulation selected for continued development
Demonstrated successful delivery at doses up to 10 times the projected therapeutic level
February 3, 2025
Vancouver, British Columbia–(Newsfile Corp. – February 3, 2025) – InMed Pharmaceuticals Inc. (NASDAQ: INM) (“InMed” or the “Company”), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today announced the selection of an intravitreal (‘IVT’) formulation for INM-089 as a drug candidate to be utilized in the Company’s ongoing development program targeting the treatment of dry age-related macular degeneration (‘AMD’).
Michael Woudenberg, InMed’s Chief Operating Officer and Senior Vice President of Chemistry, Manufacturing, and Controls, commented, “We are encouraged by the recent data demonstrating that INM-089 can be successfully delivered as an IVT formulation, offering several advantages for the continued development of this compound in the treatment of dry AMD.”
Dose ranging studies have been completed, showing that the IVT formulation of INM-089 has a favorable pharmacokinetic profile and a significant safety margin, with successful delivery at doses up to 10 times the projected therapeutic level. This is a promising development in the field of AMD treatment, as current options are limited and often have potential side effects.
The selection of the IVT formulation for continued development indicates that INM-089 has the potential to be a groundbreaking treatment for dry AMD, offering hope to patients suffering from this debilitating condition.
Overall, this announcement is a significant step forward in the development of new treatments for AMD, and brings us closer to finding effective solutions for patients in need.
How will this affect me?
As a potential future treatment for dry AMD, the development of INM-089 could have a positive impact on individuals who are affected by this condition. If successful, this drug candidate could offer a new option for managing AMD symptoms and improving overall quality of life for patients.
How will this affect the world?
The development of new treatments for diseases like AMD is important not just for individual patients, but for the healthcare system as a whole. By providing more effective and safe options for managing AMD, the world could see a reduction in healthcare costs associated with treating the condition, as well as improved outcomes for patients worldwide.
Conclusion
The selection of the IVT formulation for continued development of INM-089 is a promising development in the field of AMD treatment, offering hope to patients and paving the way for more effective solutions in the future.
